Form 4: Dermata Therapeutics CFO Receives Stock Grant
Insider Transaction (Form 4)
Hoose Kyri K. Van, SVP, CFO of Dermata Therapeutics, Inc., reported multiple transactions in common stock on August 16, 2026.
Summary
- Grant/award: acquired 102,040 Common Stock on August 16, 2026; holds 232,463 after (Direct).
- Grant/award: acquired 102,040 Series E Warrant (Right to Buy) on August 16, 2026; holds 102,040 after (Direct).
- Grant/award: acquired 102,040 Series F Warrant (Right to Buy) on August 16, 2026; holds 102,040 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Hoose Kyri K. Van — Officer (SVP, CFO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-16 | Grant/award | Common Stock | 102,040 | — | — | 232,463 |
| 2026-08-16 | Grant/award | Series E Warrant (Right to Buy) | 102,040 | — | — | 102,040 |
| 2026-08-16 | Grant/award | Series F Warrant (Right to Buy) | 102,040 | — | — | 102,040 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-16 | Grant/award (102,040 shares) |
| 2026-08-16 | Grant/award (102,040 shares) |
| 2026-08-16 | Grant/award (102,040 shares) |
Keywords
insider transaction, Form 4, DRMA, Dermata Therapeutics, Inc., neutral, Hoose Kyri K. Van
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.